Literature DB >> 18371124

Nonparametric and semiparametric group sequential methods for comparing accuracy of diagnostic tests.

Liansheng Tang1, Scott S Emerson, Xiao-Hua Zhou.   

Abstract

SUMMARY: Comparison of the accuracy of two diagnostic tests using the receiver operating characteristic (ROC) curves from two diagnostic tests has been typically conducted using fixed sample designs. On the other hand, the human experimentation inherent in a comparison of diagnostic modalities argues for periodic monitoring of the accruing data to address many issues related to the ethics and efficiency of the medical study. To date, very little research has been done on the use of sequential sampling plans for comparative ROC studies, even when these studies may use expensive and unsafe diagnostic procedures. In this article we propose a nonparametric group sequential design plan. The nonparametric sequential method adapts a nonparametric family of weighted area under the ROC curve statistics (Wieand et al., 1989, Biometrika 76, 585-592) and a group sequential sampling plan. We illustrate the implementation of this nonparametric approach for sequentially comparing ROC curves in the context of diagnostic screening for nonsmall-cell lung cancer. We also describe a semiparametric sequential method based on proportional hazard models. We compare the statistical properties of the nonparametric approach with alternative semiparametric and parametric analyses in simulation studies. The results show the nonparametric approach is robust to model misspecification and has excellent finite-sample performance.

Entities:  

Mesh:

Year:  2008        PMID: 18371124     DOI: 10.1111/j.1541-0420.2008.01000.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  10 in total

1.  Homogeneity tests of clustered diagnostic markers with applications to the BioCycle Study.

Authors:  Liansheng Larry Tang; Aiyi Liu; Enrique F Schisterman; Xiao-Hua Zhou; Catherine Chun-Ling Liu
Journal:  Stat Med       Date:  2012-06-26       Impact factor: 2.373

2.  Sample size recalculation in sequential diagnostic trials.

Authors:  Liansheng Larry Tang; Aiyi Liu
Journal:  Biostatistics       Date:  2009-10-12       Impact factor: 5.899

3.  Early termination of a two-stage study to develop and validate a panel of biomarkers.

Authors:  Joseph S Koopmeiners; Rachel Isaksson Vogel
Journal:  Stat Med       Date:  2012-10-02       Impact factor: 2.373

4.  Conditional estimation after a two-stage diagnostic biomarker study that allows early termination for futility.

Authors:  Joseph S Koopmeiners; Ziding Feng; Margaret Sullivan Pepe
Journal:  Stat Med       Date:  2012-01-12       Impact factor: 2.373

5.  A sequential conditional probability ratio test procedure for comparing diagnostic tests.

Authors:  Liansheng Tang; Ming Tan; Xiao-Hua Zhou
Journal:  J Appl Stat       Date:  2010-10-01       Impact factor: 1.404

6.  Estimating the AUC with a Graphical Lasso Method for High-dimensional Biomarkers with LOD.

Authors:  Jirui Wang; Yunpeng Zhao; Liansheng Larry Tang
Journal:  Biostat Epidemiol       Date:  2021-03-17

7.  Repeated significance tests of linear combinations of sensitivity and specificity of a diagnostic biomarker.

Authors:  Mixia Wu; Yu Shu; Zhaohai Li; Aiyi Liu
Journal:  Stat Med       Date:  2016-03-07       Impact factor: 2.373

8.  Optimal sampling ratios in comparative diagnostic trials.

Authors:  Ting Dong; Liansheng Larry Tang; William F Rosenberger
Journal:  J R Stat Soc Ser C Appl Stat       Date:  2014-04       Impact factor: 1.864

9.  Asymptotic Properties of the Sequential Empirical ROC, PPV and NPV Curves Under Case-Control Sampling.

Authors:  Joseph S Koopmeiners; Ziding Feng
Journal:  Ann Stat       Date:  2011       Impact factor: 4.028

10.  Group sequential testing of the predictive accuracy of a continuous biomarker with unknown prevalence.

Authors:  Joseph S Koopmeiners; Ziding Feng
Journal:  Stat Med       Date:  2015-11-04       Impact factor: 2.373

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.